期刊文献+

In Vitro Anti-hepatitis B Virus Activity of 2',3'-Dideoxyguanosine 被引量:2

In Vitro Anti-hepatitis B Virus Activity of 2',3'-Dideoxyguanosine
原文传递
导出
摘要 2',3'-dideoxyguanosine(DoG) has been demonstrated to inhibit duck hepatitis B virus(DHBV) replication in vivo in a duck model of HBV infection. In the current study, the in vitro antiviral effects of DoG on human and animal hepadnaviruses were investigated. Our results showed that DoG effectively inhibited HBV, DHBV, and woodchuck hepatitis virus(WHV)replication in hepatocyte-derived cells in a dose-dependent manner, with 50% effective concentrations(EC50) of 0.3 ± 0.05, 6.82 ± 0.25, and 23.0 ± 1.5 lmol/L, respectively. Similar to other hepadnaviral DNA polymerase inhibitors,DoG did not alter the levels of intracellular viral RNA but induced the accumulation of a less-than-full-length viral RNA species, which was recently demonstrated to be generated by RNase H cleavage of pgRNA. Furthermore, using a transient transfection assay, DoG showed similar antiviral activity against HBV wild-type, 3TC-resistant rtA181 V, and adefovirresistant rtN236T mutants. Our results suggest that DoG has potential as a nucleoside analogue drug with anti-HBV activity. 2',3'-dideoxyguanosine(DoG) has been demonstrated to inhibit duck hepatitis B virus(DHBV) replication in vivo in a duck model of HBV infection. In the current study, the in vitro antiviral effects of DoG on human and animal hepadnaviruses were investigated. Our results showed that DoG effectively inhibited HBV, DHBV, and woodchuck hepatitis virus(WHV)replication in hepatocyte-derived cells in a dose-dependent manner, with 50% effective concentrations(EC50) of 0.3 ± 0.05, 6.82 ± 0.25, and 23.0 ± 1.5 lmol/L, respectively. Similar to other hepadnaviral DNA polymerase inhibitors,DoG did not alter the levels of intracellular viral RNA but induced the accumulation of a less-than-full-length viral RNA species, which was recently demonstrated to be generated by RNase H cleavage of pgRNA. Furthermore, using a transient transfection assay, DoG showed similar antiviral activity against HBV wild-type, 3TC-resistant rtA181 V, and adefovirresistant rtN236T mutants. Our results suggest that DoG has potential as a nucleoside analogue drug with anti-HBV activity.
出处 《Virologica Sinica》 SCIE CAS CSCD 2018年第6期538-544,共7页 中国病毒学(英文版)
基金 supported in part by the Program for New Century Excellent Talents in University (Program No. NCET-12-0975) the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry Jiangsu Overseas research & training program for University Prominent Young and Middle-aged Teachers and Presidents (for Pinghu Zhang) Qinghai Province High-end Innovative Talent Thousand Talents Program (for Pinghu Zhang)
关键词 HBV WOODCHUCK HEPATITIS virus(WHV) HEPATITIS B ANTIVIRAL NUCLEOSIDE ANALOGUES HBV Woodchuck hepatitis virus(WHV) Hepatitis B Antiviral Nucleoside analogues
  • 相关文献

参考文献3

二级参考文献222

  • 1Janssen HL, van Zonneveld M, Schalm SW. Hepatitis B. N Engl J Med 2004; 350: 2719-20.
  • 2White AJ. Mitochondrial toxicity and HIV therapy. Sex Transm Infect 2001; 77: 158-73.
  • 3Kees Brinkman, Hadewych J M ter Hofstede. Mitochondrial toxicity of nucleoside analogue reverse trancriptase inhibitors: lactic acidosis, risk factors and therapeutic options. AIDS Rev 1999; 1: 140-6.
  • 4Birkus G, Hitchcock M J, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46: 716-23.
  • 5Brinkman K, ter Hofstede H J, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735-44.
  • 6Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 1423-30.
  • 7John M, Nolan D, Mallal S. Antiretroviral therapy and the lipodystrophy syndrome. Antivir Ther 2001; 6: 9-20.
  • 8Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 2000; 22: 911-36.
  • 9Lewis W, Copeland WC, Day BJ. Mitochondrial DNA depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors. Lab Invest 2001; 81: 777-90.
  • 10Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991; 337: 508-10.

共引文献28

同被引文献12

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部